Health Management Associates, Inc.
Health Management Associates — Proxy Contest (June 2013)
47 slides from Health Management Associates's proxy contest presentation, Jun 25, 2013
Slide 1: Revitalize HMA - The Case for Change
Revitalize HMA - The Case for Change Presentation to HMA Shareholders June 2013
Slide 2: Executive Summary - The Case for Change at HMA
PAGE 2 Executive Summary - The Case for Change at HMA 1 Consistent track record of underperformance 2 Substandard financial management and focus 3 Elevated number of compliance related issues and concerns 4 Misalignment between Board direction and shareholder priorities 5 Sitting Board is insular an
Slide 3: Executive Summary - The Case for Change at HMA
PAGE 3 Executive Summary - The Case for Change at HMA The Lost Decade In the decade ending 2012, HMA, under the direction and guidance of substantially all of the sitting Board, delivered <1% total shareholder value while investors in the Hospital Group and the S&P garnered an 39% and 99% total shar
Slide 4: Executive Summary - Myopic focus on M&A
PAGE 4 Myopic focus on M&A, no balanced capital allocation strategy During the Lost Decade management and the Board followed a myopic strategy of unfocused M&A growth HMA demonstrated 86% EBITDA growth in the 10 years ending 2012, but <1% total shareholder return HMA is the only company in the Hospi
Slide 5: Executive Summary - Shareholder-unfriendly defensive tactics
PAGE 5 Executive Summary - The Case for Change at HMA Shareholder-unfriendly defensive tactics Rather than constructively engaging shareholders in dialogue, Board put in place a Poison Pill Board stated that it hired bankers and legal advisors "in connection with accumulation of shares by Glenview"
Slide 6: The Lost Decade - Consistent Underperformance
(CHART) PAGE 6 The Lost Decade - Consistent Underperformance Source: Bloomberg total shareholder return analysis. 1. "Hospital Group" includes HCA, THC, CYH, LPNT, and UHS except where indicated. 2. HCA reflects total compounded shareholder return from 1/1/03 to 11/17/06 (leveraged buyout date) and
Slide 7: Total Shareholder Return - Consistent Underperformance
PAGE 7 Total Shareholder Return - Consistent Underperformance HMA's total shareholder return has sharply and consistently lagged other publicly traded hospital companies Total Shareholder Return 3-year period ending 5/6/13 Total Shareholder Return 5-year period ending 5/6/13 Total Shareholder Return
Slide 8: Substandard Financial Management and Focus
PAGE 8 Substandard Financial Management and Focus Source: Company filings, press releases, earnings calls and Morgan Stanley equity research. Guidance based on HMA investor communications/documents: 1) 10/22/02 Q4 earnings call transcript, 2) 10/21/03 Q4 earnings call transcript, 3) 10/26/04 Q4 earn
Slide 9: Substandard Financial Management and Focus
PAGE 9 Substandard Financial Management and Focus Note: "Hospital Group" includes HCA, THC, CYH, LPNT, and UHS (acute only). Source: Company filings, press releases, earnings calls and Morgan Stanley equity research. Same-store Admissions Growth Relative to its hospital peers, HMA has demonstrated c
Slide 10: HMA Guidance vs Performance
PAGE 10 Metric HMA Guidance Consensus Estimates HMA Performance Result (Relative to Guidance) Admissions (2010)1 1% to 2% -1.8% MISSED (2.8-3.8%) Admissions (2011)2 0% to 2% -4.0% MISSED (4.0-6.0%) Earnings per Share (2011)2 72-76c 71c MISSED (1.4-6.6%) Admissions (2012)2 -2% to 0% -4.8% MISSED (2.8
Slide 11: CFO Credibility with Investors
PAGE 11 AL, OK, NC, PA, and MS all paid industry provider fees in 3Q12, but the CFO claimed HMA received none Analyst on earnings call: "Did you see any provider fees from any of your states in that 6.9% number?"1 HMA CFO: "No." Financial leadership failed to establish credibility with the investor
Slide 12: CFO lack of seriousness in meetings
PAGE 12 The CFO consistently shows a lack of seriousness in meetings and responds to questions with laughter and non-responsive answers - even after major earnings misses and significant declines in the stock On April 10, HMA pre-announced poor 1Q13 results: HMA missed consensus EBITDA by 21%, conse
Slide 13: Suboptimal Capital Allocation Policy
Suboptimal Capital Allocation Policy 1. "Long-Term Interest Rates", Ben S. Bernanke, p. 9-10. 2. HMA 1Q13 earnings call transcript. 3/1/13: Remarks by Ben Bernanke at the Annual Monetary/Macroeconomics Conference "The basic message is clear--long-term interest rates are expected to rise gradually ov
Slide 14: Suboptimal Capital Allocation Policy
Suboptimal Capital Allocation Policy Fixed Rate Debt (% of total) Variable Rate Debt (% of total) Hospital Competitors1 83% 17% HMA2 41% 59% 1. Weighted average fixed/variable debt percentages of CYH, HCA, LPNT, THC, UHS and VHS net of interest rate swaps. Sourced from most recent 10-Q filings. 2. P
Slide 15: Compliance Concerns Have Led to Multiple Investigations
PAGE 15 Compliance Concerns Have Led to Multiple Investigations Former CEO of Physicians Regional Medical Center Michael Mastej filed a lawsuit against HMA in 2010 Mastej's case claimed that HMA used incentives to increase physician Medicare patient referrals to HMA hospitals Similar allegations of
Slide 16: Misaligned incentive compensation tied to EBITDA growth
PAGE 16 The Board's misaligned incentive compensation structure has been tied exclusively to aggregate EBITDA growth - as opposed to any per share metrics Board has misguided view that aggregate measures like EBITDA growth drive share price performance, whereas they place no emphasis on per share me
Slide 17: HMA 2012 Performance and Management Incentives
PAGE 17 HMA 2012 Performance HMA Guidance Actual Result Adjusted EBITDA1 $875-925M $871M MISSED (0.4-6%) Earnings per Share1 80-90c 75c MISSED (6-17%) Admissions -2% to 0% -4.8% MISSED (2.8-4.8%) HMA 2012 Management Incentives Result Performance Target set by Board: Adjusted EBITDA Target: $924M Act
Slide 18: HMA Misapplied Management Incentive Compensation
PAGE 18 HMA Misapplied Management Incentive Compensation Paid to Hospitals that show "meaningful use" of electronic records Paid by the federal government Established in 2009 by the "stimulus package" Available 2011-2016 HMA's 2012 guidance cited an estimated $90- 120M in HITECH meaningful use reimb
Slide 19: HMA Misapplied Management Incentive Compensation
PAGE 19 HMA Misapplied Management Incentive Compensation Date Reference HMA Management Announcement HITECH Incentive Payments in Adj. Adjusted EBITDA January 9, 2012 HMA Press Release Issued 2012 guidance: Adjusted EBITDA of $875-925M Excluded March 26, 2012 Barclays High-Yield Bond Conference Reite
Slide 20: HMA Misapplied Management Incentive Compensation
PAGE 20 HMA Misapplied Management Incentive Compensation On a May 3rd call with Glenview, HMA's CFO insisted that the $924M Performance Target included HITECH incentive payments On a subsequent call on May 15th with Glenview, Chairman Schoen & Lead Director Knox confirmed the $924M Performance Targe
Slide 21: Ineffective Incentives & Strategy Led to Near Zero Shareholder Growth
PAGE 21 Ineffective Incentives & Strategy Have Led to Near Zero Shareholder Growth in 10 Years According to a recent HMA proxy, the Board "believes that Adjusted EBITDA provides a simple and understandable measure of our recurring profitability and it is highly correlated to our stock price performa
Slide 22: The Board Has No Strategic Vision, only Buying Boxes
PAGE 22 The Board Has No Strategic Vision, only "Buying Boxes" HMA claims to have targeted EBITDA growth through M&A... ...but their poor track record is reflected in HMA's stock price The Board recently hired outside advisors to help focus its M&A strategy, citing the discontinuity of prior acquisi
Slide 23: Suboptimal Capital Allocation Policy
PAGE 23 Suboptimal Capital Allocation Policy (CHART) Share repurchase ($M) Share repurchase 0% 11% 10% 46% 70%1 23% M&A 100% 78% 87% 54% 26% 29% Dividend 0% 11% 3% 0% 3% 48% Total ($M) $656 $715 $846 $591 $1,125 $6,622 Average price of repurchase N/A $39.12 $24.72 $36.69 $23.652 $18.61 Stock price o
Slide 24: Suboptimal Capital Allocation Policy
1. EBITDA estimates reflect the mid-point of HMA's guidance respectively. 2. Balance sheet stats as of 1Q12 actual. 3. Balance sheet stats as of 3Q12 actual. Historical intransigence about considering stock repurchases demonstrates a deep seated bias by HMA's Board to even consider share repurchases
Slide 25: Capital Allocation to Share Repurchase Consistently Outperforms
PAGE 25 Capital Allocation to Share Repurchase Consistently Outperforms Companies that consistently invested their cash flow and resources in a share repurchase program have generated material outperformance over the past 5, 10 and 15 year periods, leading to an average of more than 4% greater annua
Slide 26: The Board is Now Searching for Their 5th CEO
PAGE 26 The Board is Now Searching for Their 5th CEO in 13 Years CEO Gary Newsome's departure announced May 28 New CEO expected by Newsome's departure July 31 Board Committee leading the search for a new CEO is comprised of: William Schoen Kent Dauten Robert Knox Donald Kiernan Dauten & Knox also se
Slide 27: Excessive Tenure: The Board is Insular & Stale
PAGE 27 Excessive Tenure: The Board is Insular & Stale HMA's peers have not made the same mistake Average tenure for the HMA Board: ~17 years HMA Director Year Appointed Tenure (Years) Dauten 1981 32 Schoen 1983 30 Knox 1985 28 Westerfield 2000 13 Kiernan 2001 12 Steere 2003 10 O'Meara 2005 8 Goldsc
Slide 28: The Board Failed to Consider Alternatives to Create Shareholder Value
PAGE 28 The Board Failed to Consider Alternatives to Create Shareholder Value "The Rights will cause substantial dilution to any person or group that attempts to acquire the Corporation without the approval of the Board of Directors" "The determination of the Board of Directors to redeem the Rights
Slide 29: May 2013 Timeline
PAGE 29 The Board Failed to Consider Alternatives to Create Shareholder Value May 2013 Timeline Hostile actions indicative of an insular board No calls after the Annual Meeting, despite two offers for a Board-level meeting HMA cancelled its management meeting with Glenview, telling investors it was
Slide 30: Defensive Insular Tactics Are Not a New Phenomenon
PAGE 30 Defensive Insular Tactics Are Not a New Phenomenon - 2007 Case Study 1. Per Bloomberg - with divided reinvestment. 2. Note that the Total Shareholder Return from 1/17/2007 through 5/6/2013 has been 0.2%. Given the LBO of HCA earlier in 2006, there was confirmed Private Equity interest in HMA
Slide 31: Shareholders' Value-Enhancing Solution: Revitalize HMA
PAGE 31 Shareholders' Value-Enhancing Solution: Revitalize HMA
Slide 32: Executive Summary - Revitalize HMA
PAGE 32 Executive Summary - Revitalize HMA "And in the specific case of HMA, we think that this is precisely the sort of action that could fix long-standing problems. In short, we think that Glenview is pursuing precisely the correct course and believe that it can be successful in building a consens
Slide 33: Executive Summary - Revitalize HMA
PAGE 33 Executive Summary - Revitalize HMA Elect a blue-chip Board - to serve for the benefit of ALL shareholders, not for ONE shareholder The nominees put forth represent leaders in their fields with expertise in areas critical to success and prosperity at HMA - including facilities and payer manag
Slide 34: Executive Summary - Revitalize HMA
PAGE 34 Executive Summary - Revitalize HMA Glenview Capital has identified a team from Alvarez & Marsal (A&M) to help transition as potential management during the initial transition and stabilization period at HMA, as necessary Guy Sansone, Head of the Healthcare Group, has over 17 years of experie
Slide 35: Proposed Board of Directors
Proposed Board of Directors Mary Taylor Behrens Steve Epstein Kirk Gorman Stephen Guillard Earl Holland John McCarty Steve Shulman Peter Urbanowicz New Proposed Independent Board of Directors PAGE 35
Slide 36: A Constructive Path Forward
PAGE 36 A Constructive Path Forward Should long-term independence be the value maximizing strategy, then embark on a long-term HR program to build management talent depth and culture Evaluate with an open mind all avenues for shareholder value creation Establish an interim management team with exper
Slide 37: Maintain Continuity - Proven Transitional Management
PAGE 37 Maintain Continuity - Proven Transitional Management Glenview Capital has identified a team from Alvarez & Marsal (A&M) to help transition as potential management during the initial transition and stabilization period at HMA, as necessary Guy Sansone, Head of the Healthcare Group, has over 1
Slide 38: Board Nominees - Mary Taylor Behrens
PAGE 38 Revitalize HMA - Board Nominees Mary Taylor Behrens Extensive healthcare finance experience: Managing Director in healthcare investment banking at Merrill Lynch & Co. Inc. and Head of the Americas region of Merrill Lynch Investment Managers Head of Human Resources and member of Executive Com
Slide 39: Board Nominees - Steve Epstein
PAGE 39 Revitalize HMA - Board Nominees Extensive healthcare legal experience: Founder and named partner of Epstein Becker & Green, a leading law firm in health care law which he founded in 1973 Relevant board experience: Currently sits on the boards of a number of healthcare companies, including se
Slide 40: Board Nominees - Kirk Gorman
PAGE 40 Revitalize HMA - Board Nominees Executive hospital experience: Executive Vice President and Chief Financial Officer of Philadelphia's Jefferson Health System since September 2003 Senior Vice President and Chief Financial Officer of Universal Health Services and President and Chief Financial
Slide 41: Board Nominees - Stephen Guillard
PAGE 41 Revitalize HMA - Board Nominees Stephen Guillard Executive healthcare facilities experience: Executive Vice President of HCR ManorCare from June 2005 and Chief Operating Officer from January 2007 Chief Executive Officer of Harborside Healthcare from March 1996 to June 2005 and Chief Executiv
Slide 42: Board Nominees - Earl Holland
PAGE 42 Revitalize HMA - Board Nominees Executive hospital experience: Vice Chairman and Chief Operating Officer of HMA from 1999 to January 2001 and with HMA in other functions since 1981 Relevant board experience and affiliations: Director of Team Health Holdings since August 2001 Director of Corn
Slide 43: Board Nominees - John McCarty
PAGE 43 Revitalize HMA - Board Nominees Executive healthcare services experience: From February 2006 until his retirement in December 2009, Mr. McCarty served as the Executive Vice President and Chief Financial Officer of SHPS, Inc., a provider of health improvement programs From October 2011 to May
Slide 44: Board Nominees - Steve Shulman
PAGE 44 Revitalize HMA - Board Nominees Steve Shulman Executive healthcare services experience: Chairman and Chief Executive Officer of Magellan Health Services from 2002 to 2008 Chairman, President and Chief Executive Officer of Prudential Healthcare from 1997 to 1999 Previously served in leadershi
Slide 45: Board Nominees - Peter Urbanowicz
PAGE 45 Revitalize HMA - Board Nominees Peter Urbanowicz Extensive healthcare regulatory and legal experience: Managing Director at Alvarez & Marsal's Healthcare Industry Group since May 2008, where he leads the firm's healthcare compliance practice Served as Executive Vice President, General Counse
Slide 46: Who is Glenview Capital
PAGE 46 Who is Glenview Capital $6B+ New York based Hedge Fund Not an activist fund - HMA is the first time Glenview Capital has proposed fully replacing BOD members Investor in HMA for more than 2 years Own 14.6% of HMA Have $2B in capital invested in the hospital sector Historical track record of
Slide 47: Glenview consent solicitation legend
PAGE 47 GLENVIEW CAPITAL PARTNERS, L.P., GLENVIEW CAPITAL MASTER FUND, LTD., GLENVIEW INSTITUTIONAL PARTNERS, L.P., GLENVIEW OFFSHORE OPPORTUNITY MASTER FUND, LTD., GLENVIEW CAPITAL OPPORTUNITY FUND, L.P., GLENVIEW CAPITAL MANAGEMENT, LLC AND LARRY ROBBINS (COLLECTIVELY, "GLENVIEW") INTEND TO FILE W
Health Management Associates — Proxy Contest (June 2013) on 6ix